These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

337 related items for PubMed ID: 16282596

  • 1. Potassium channels, memory T cells, and multiple sclerosis.
    Beeton C, Chandy KG.
    Neuroscientist; 2005 Dec; 11(6):550-62. PubMed ID: 16282596
    [Abstract] [Full Text] [Related]

  • 2. Kv1.3 potassium channels as a therapeutic target in multiple sclerosis.
    Rangaraju S, Chi V, Pennington MW, Chandy KG.
    Expert Opin Ther Targets; 2009 Aug; 13(8):909-24. PubMed ID: 19538097
    [Abstract] [Full Text] [Related]

  • 3. Potassium channels as therapeutic targets for autoimmune disorders.
    Wulff H, Beeton C, Chandy KG.
    Curr Opin Drug Discov Devel; 2003 Sep; 6(5):640-7. PubMed ID: 14579513
    [Abstract] [Full Text] [Related]

  • 4. Targeting effector memory T-cells with Kv1.3 blockers.
    Wulff H, Pennington M.
    Curr Opin Drug Discov Devel; 2007 Jul; 10(4):438-45. PubMed ID: 17659485
    [Abstract] [Full Text] [Related]

  • 5. Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases.
    Schmitz A, Sankaranarayanan A, Azam P, Schmidt-Lassen K, Homerick D, Hänsel W, Wulff H.
    Mol Pharmacol; 2005 Nov; 68(5):1254-70. PubMed ID: 16099841
    [Abstract] [Full Text] [Related]

  • 6. Potassium channel expression in human CD4+ regulatory and naïve T cells from healthy subjects and multiple sclerosis patients.
    Varga Z, Csepany T, Papp F, Fabian A, Gogolak P, Toth A, Panyi G.
    Immunol Lett; 2009 Jun 04; 124(2):95-101. PubMed ID: 19409928
    [Abstract] [Full Text] [Related]

  • 7. Toxins Targeting the Kv1.3 Channel: Potential Immunomodulators for Autoimmune Diseases.
    Zhao Y, Huang J, Yuan X, Peng B, Liu W, Han S, He X.
    Toxins (Basel); 2015 May 19; 7(5):1749-64. PubMed ID: 25996605
    [Abstract] [Full Text] [Related]

  • 8. Kv1.3 channel as a promising therapeutic target for acquired aplastic anemia.
    Hu X, Xu C, Cong Y.
    Med Hypotheses; 2008 May 19; 70(5):1072. PubMed ID: 18158221
    [No Abstract] [Full Text] [Related]

  • 9. The immunopathogenesis of multiple sclerosis.
    Giovannoni G.
    Baillieres Clin Neurol; 1997 Oct 19; 6(3):387-407. PubMed ID: 10101580
    [Abstract] [Full Text] [Related]

  • 10. Targeting potassium channels Kv1.3 and KC a 3.1: routes to selective immunomodulators in autoimmune disorder treatment?
    Wang J, Xiang M.
    Pharmacotherapy; 2013 May 19; 33(5):515-28. PubMed ID: 23649812
    [Abstract] [Full Text] [Related]

  • 11. Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease.
    Weiner HL.
    Arch Neurol; 2004 Oct 19; 61(10):1613-5. PubMed ID: 15477521
    [No Abstract] [Full Text] [Related]

  • 12. Biophysical and pharmacological aspects of K+ channels in T lymphocytes.
    Panyi G.
    Eur Biophys J; 2005 Aug 19; 34(6):515-29. PubMed ID: 16184309
    [Abstract] [Full Text] [Related]

  • 13. Blockade of Ca2+-activated K+ channels in T cells: an option for the treatment of multiple sclerosis?
    Madsen LS, Christophersen P, Olesen SP.
    Eur J Immunol; 2005 Apr 19; 35(4):1023-6. PubMed ID: 15770695
    [Abstract] [Full Text] [Related]

  • 14. [Multiple sclerosis: from the immune system to inflammatory demyelination and irreversible neurodegeneration].
    Sindic CJ.
    Bull Mem Acad R Med Belg; 2002 Apr 19; 157(7-9):391-8; discussion 398-400. PubMed ID: 12647378
    [Abstract] [Full Text] [Related]

  • 15. Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block.
    Matheu MP, Beeton C, Garcia A, Chi V, Rangaraju S, Safrina O, Monaghan K, Uemura MI, Li D, Pal S, de la Maza LM, Monuki E, Flügel A, Pennington MW, Parker I, Chandy KG, Cahalan MD.
    Immunity; 2008 Oct 17; 29(4):602-14. PubMed ID: 18835197
    [Abstract] [Full Text] [Related]

  • 16. Peptide blockers of Kv1.3 channels in T cells as therapeutics for autoimmune disease.
    Chandy KG, Norton RS.
    Curr Opin Chem Biol; 2017 Jun 17; 38():97-107. PubMed ID: 28412597
    [Abstract] [Full Text] [Related]

  • 17. Curcumin serves as a human kv1.3 blocker to inhibit effector memory T lymphocyte activities.
    Lian YT, Yang XF, Wang ZH, Yang Y, Yang Y, Shu YW, Cheng LX, Liu K.
    Phytother Res; 2013 Sep 17; 27(9):1321-7. PubMed ID: 23132777
    [Abstract] [Full Text] [Related]

  • 18. Multiple sclerosis: a complicated picture of autoimmunity.
    McFarland HF, Martin R.
    Nat Immunol; 2007 Sep 17; 8(9):913-9. PubMed ID: 17712344
    [Abstract] [Full Text] [Related]

  • 19. Immunologic aspects of multiple sclerosis.
    Taylor RS.
    Phys Med Rehabil Clin N Am; 1998 Aug 17; 9(3):525-36, v. PubMed ID: 9894106
    [Abstract] [Full Text] [Related]

  • 20. Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment.
    Judge SI, Bever CT.
    Pharmacol Ther; 2006 Jul 17; 111(1):224-59. PubMed ID: 16472864
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.